138 related articles for article (PubMed ID: 17251982)
1. Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects.
van Giersbergen PL; Treiber A; Schneiter R; Dietrich H; Dingemanse J
Clin Pharmacol Ther; 2007 Mar; 81(3):414-9. PubMed ID: 17251982
[TBL] [Abstract][Full Text] [Related]
2. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.
Treiber A; Schneiter R; Häusler S; Stieger B
Drug Metab Dispos; 2007 Aug; 35(8):1400-7. PubMed ID: 17496208
[TBL] [Abstract][Full Text] [Related]
3. The drug-drug interaction potential of rifampicin.
Srinivas NR
Clin Ther; 2008 Oct; 30(10):1932-3. PubMed ID: 19014849
[No Abstract] [Full Text] [Related]
4. Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin.
Dingemanse J; Schaarschmidt D; van Giersbergen PL
Clin Pharmacokinet; 2003; 42(3):293-301. PubMed ID: 12603176
[TBL] [Abstract][Full Text] [Related]
5. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
6. Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers.
Markert C; Schweizer Y; Hellwig R; Wirsching T; Riedel KD; Burhenne J; Weiss J; Mikus G; Haefeli WE
Br J Clin Pharmacol; 2014 Jan; 77(1):141-8. PubMed ID: 23738582
[TBL] [Abstract][Full Text] [Related]
7. Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers.
Werner D; Werner U; Meybaum A; Schmidt B; Umbreen S; Grosch A; Lestin HG; Graf B; Zolk O; Fromm MF
Clin Pharmacokinet; 2008; 47(5):323-32. PubMed ID: 18399713
[TBL] [Abstract][Full Text] [Related]
8. CYP3A inductive potential of the rifamycins, rifabutin and rifampin, in the rabbit.
Weber A; Kaplan M; Chughtai SA; Cohn LA; Smith AL; Unadkat JD
Biopharm Drug Dispos; 2001 May; 22(4):157-68. PubMed ID: 11745918
[TBL] [Abstract][Full Text] [Related]
9. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.
Kerbusch T; Jansen RL; Mathôt RA; Huitema AD; Jansen M; van Rijswijk RE; Beijnen JH
Clin Pharmacol Ther; 2001 Aug; 70(2):132-41. PubMed ID: 11503007
[TBL] [Abstract][Full Text] [Related]
10. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation.
Tirona RG; Leake BF; Wolkoff AW; Kim RB
J Pharmacol Exp Ther; 2003 Jan; 304(1):223-8. PubMed ID: 12490595
[TBL] [Abstract][Full Text] [Related]
11. Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole.
van Giersbergen PL; Halabi A; Dingemanse J
Br J Clin Pharmacol; 2002 Jun; 53(6):589-95. PubMed ID: 12047483
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokinetics.
Gashaw I; Kirchheiner J; Goldammer M; Bauer S; Seidemann J; Zoller K; Mrozikiewicz PM; Roots I; Brockmöller J
Clin Pharmacol Ther; 2003 Nov; 74(5):448-57. PubMed ID: 14586385
[TBL] [Abstract][Full Text] [Related]
13. Dual effects of rifampin on the pharmacokinetics of atrasentan.
Xiong H; Carr RA; Locke CS; Katz DA; Achari R; Doan TT; Wang P; Jankowski JR; Sleep DJ
J Clin Pharmacol; 2007 Apr; 47(4):423-9. PubMed ID: 17389551
[TBL] [Abstract][Full Text] [Related]
14. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
Bolton AE; Peng B; Hubert M; Krebs-Brown A; Capdeville R; Keller U; Seiberling M
Cancer Chemother Pharmacol; 2004 Feb; 53(2):102-6. PubMed ID: 14605865
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.
Dingemanse J; van Giersbergen PL
Clin Pharmacokinet; 2004; 43(15):1089-115. PubMed ID: 15568889
[TBL] [Abstract][Full Text] [Related]
16. Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate.
Kharasch ED; Whittington D; Hoffer C
Anesthesiology; 2004 Sep; 101(3):729-37. PubMed ID: 15329598
[TBL] [Abstract][Full Text] [Related]
17. Influence of St. John's wort on the steady-state pharmacokinetics and metabolism of bosentan.
Markert C; Ngui P; Hellwig R; Wirsching T; Kastner IM; Riedel KD; Burhenne J; Weiss J; Mikus G; Haefeli WE
Int J Clin Pharmacol Ther; 2014 Apr; 52(4):328-36. PubMed ID: 24472406
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.
Yee KL; Khalilieh SG; Sanchez RI; Liu R; Anderson MS; Manthos H; Judge T; Brejda J; Butterton JR
Clin Drug Investig; 2017 Jul; 37(7):659-667. PubMed ID: 28353169
[TBL] [Abstract][Full Text] [Related]
19. Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers.
Gotzkowsky SK; Dingemanse J; Lai A; Mottola D; Laliberte K
J Clin Pharmacol; 2010 Jul; 50(7):829-34. PubMed ID: 20133511
[TBL] [Abstract][Full Text] [Related]
20. Bosentan and Rifampin Interactions Modulate Influx Transporter and Cytochrome P450 Expression and Activities in Primary Human Hepatocytes.
Han KM; Ahn SY; Seo H; Yun J; Cha HJ; Shin JS; Kim YH; Kim H; Park HK; Lee YM
Biomol Ther (Seoul); 2017 May; 25(3):288-295. PubMed ID: 28173639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
